New antibody treatment aims to shield transplant patients from dangerous virus

NCT ID NCT05370976

Terminated Disease control Sponsor: University Hospital, Lille Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested a drug called Cytotect, which contains antibodies against the CMV virus, to prevent CMV infection in people who had a stem cell transplant and developed graft-versus-host disease (GVHD). These patients are at high risk for CMV, and current antiviral drugs often cause serious side effects. The trial was very small and was stopped early, so we cannot draw firm conclusions about how well Cytotect works.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Cytotect (hyperimmune anti-CMV immunoglobulin)
What this could lead to: If it works, this could provide a safer way to prevent CMV infection in high-risk transplant patients, avoiding the severe side effects of current antiviral drugs.
What could go wrong: This was a very small, early-phase trial that was terminated early with only 2 participants, so results are not reliable. The drug may not prevent CMV infection effectively.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE GRAFT VERSUS HOST DISEASE GRADE II-IV are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute graft versus host disease cytomegalovirus infection prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CYTOMEGALOVIRUS INFECTIONS

Contacts and locations

Locations

Hop Claude Huriez Chu Lille

Lille, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.